Encouraging Results With Nivolumab in Metastatic Anal CancerEncouraging Results With Nivolumab in Metastatic Anal Cancer

Phase 2 trial results showed that metastatic and refractory squamous cell carcinoma of the anal canal responded to a PD-1 inhibitor. Medscape Medical News

Source: Medscape Medical News Headlines - June 15, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news